Beclomethasone (QVAR) vs ciclesonide (Alvesco)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

Beclomethasone (QVAR)

Marketed by Teva Pharmaceutical Industries

Approved in Asthmasmall molecule (corticosteroid)
Reliable signal

NCT02513160 · Phase 3 · completed

The trial randomized 425 participants across beclomethasone and placebo groups and used quadruple blinding with matched placebo devices. Its primary endpoint was the regulator-accepted asthma measure FEV1, and each prespecified beclomethasone-versus-placebo comparison was statistically significant, supporting a strong evidence grade.

Reported efficacy

Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk)) (Day 1 (baseline), Weeks 2, 4, 8, 12): Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results). (mixed)

Result source: NCT02040766

ciclesonide (Alvesco)

Marketed by Azurity Pharmaceuticals and partners

Approved in Asthmasmall molecule (corticosteroid)
Reliable signal

NCT00163397 · Phase 3 · completed

This was a randomized, double-blind, active-controlled trial comparing ciclesonide to budesonide, using lung function (FEV1) as the primary endpoint -- a regulator-accepted objective measure for asthma. The trial was designed as a non-inferiority comparison, and the prespecified margin test succeeded, meaning ciclesonide performed comparably to the active comparator on its primary measure.

Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.

Reported efficacy

Change from baseline to Week 16 in FEV1: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone (met)

Result source: NCT00174720

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBeclomethasone (QVAR)ciclesonide (Alvesco)
Severe exacerbations, annualised rate—Not posted · NCT00109668—Not posted · NCT00174720
Trough FEV1, change—Not posted · NCT00109668—Not posted · NCT00174720
ACQ-5, change—Not posted · NCT00109668—Not posted · NCT00174720
OCS dose reduction—Not posted · NCT00109668—Not posted · NCT00174720

Severe exacerbations, annualised rate

Beclomethasone (QVAR)
—Not posted · NCT00109668
ciclesonide (Alvesco)
—Not posted · NCT00174720

Trough FEV1, change

Beclomethasone (QVAR)
—Not posted · NCT00109668
ciclesonide (Alvesco)
—Not posted · NCT00174720

ACQ-5, change

Beclomethasone (QVAR)
—Not posted · NCT00109668
ciclesonide (Alvesco)
—Not posted · NCT00174720

OCS dose reduction

Beclomethasone (QVAR)
—Not posted · NCT00109668
ciclesonide (Alvesco)
—Not posted · NCT00174720
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Beclomethasone (QVAR)
Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results). NCT02040766 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Beclomethasone (QVAR): 0 of 4 rows · ciclesonide (Alvesco): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricciclesonide (Alvesco)
Dropout rate
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
11.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Discontinued due to AEs
—a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
5.1%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Serious AEs
0%a
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.8%
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy
Most frequent reported AEs
a
headaches/migraine 23.8% (placebo 22.7%)
respiratory infections 19% (placebo 18.2%)
bilateral otitis media 4.8% (placebo 0%)
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

ciclesonide (Alvesco)

Lower Leg Growth Velocity MM Wk 0.23 vs 0.33 Beconase and QVAR mm @ 52wk
absolute value · mm
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
show 1 more result
0.23 vs 0.51 placebo mm @ 52wk
NCT01550471 · Phase 4 · registry result, not featured evidence · combination · Asthma · phase 4
ACQ -0.76 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT00404547 · Phase 4 · registry result, not featured evidence · monotherapy

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone (QVAR)'s landscape · ciclesonide (Alvesco)'s landscape